Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease

Kidney International

Volumn 90, Issue 5, 2016, Pages 985-996

  Singh, Saurav ^a   Grabner, Alexander ^a   Yanucil, Christopher ^a   Schramm, Karla ^a   Czaya, Brian ^a   Krick, Stefanie ^a   Czaja, Mark J ^b   Bartz, Rene ^c   Abraham, Reimar ^c   Di Marco, Giovana S ^d   Brand, Marcus ^d   Wolf, Myles ^e   Faul, Christian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c U3 Pharma GmbH   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

calcineurin; chronic kidney disease; FGF23; hepatocytes; inflammation

Indexed keywords

BLOCKING ANTIBODY; C REACTIVE PROTEIN; CALCINEURIN; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KLOTHO PROTEIN; BETA GLUCURONIDASE; CYTOKINE; FIBROBLAST GROWTH FACTOR; PHOSPHOLIPASE C GAMMA; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOSTIMULATION; INFLAMMATION; KNOCKOUT MOUSE; LIVER CELL; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT MODEL; SIGNAL TRANSDUCTION; WILD TYPE MOUSE; ANIMAL; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; PRIMARY CELL CULTURE; RAT;

ANIMALS; CALCINEURIN; CYTOKINES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HEPATOCYTES; HUMANS; INFLAMMATION; MICE; NFATC TRANSCRIPTION FACTORS; PHOSPHOLIPASE C GAMMA; PRIMARY CELL CULTURE; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84979011044     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.05.019     Document Type: Article

References (71)

1. 1 Quarles, L.D., Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118 (2008), 3820–3828.
2. 2 Urakawa, I., Yamazaki, Y., Shimada, T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006), 770–774.
3. 3 Kurosu, H., Ogawa, Y., Miyoshi, M., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281 (2006), 6120–6123.
4. 4 Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 (2007), 4003–4008.
5. 5 Wolf, M., Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21 (2010), 1427–1435.
6. 6 Gutierrez, O., Isakova, T., Rhee, E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16 (2005), 2205–2215.
7. 7 Isakova, T., Wahl, P., Vargas, G.S., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 (2011), 1370–1378.
8. 8 Shimada, T., Urakawa, I., Isakova, T., et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95 (2010), 578–585.
9. 9 Gutierrez, O.M., Mannstadt, M., Isakova, T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008), 584–592.
10. 10 Jean, G., Terrat, J.C., Vanel, T., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24 (2009), 2792–2796.
11. 11 Parker, B.D., Schurgers, L.J., Brandenburg, V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152 (2010), 640–648.
12. 12 Isakova, T., Xie, H., Yang, W., et al., for the CRIC Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
13. 13 Ornitz, D.M., Itoh, N., Fibroblast growth factors. Genome Biol, 2, 2001 REVIEWS3005.
14. 14 Eswarakumar, V.P., Lax, I., Schlessinger, J., Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005), 139–149.
15. 15 Kouhara, H., Hadari, Y.R., Spivak-Kroizman, T., et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89 (1997), 693–702.
16. 16 Mohammadi, M., Honegger, A.M., Rotin, D., et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 11 (1991), 5068–5078.
17. 17 Vainikka, S., Joukov, V., Wennstrom, S., et al. Signal transduction by fibroblast growth factor receptor-4 (FGFR-4): comparison with FGFR-1. J Biol Chem 269 (1994), 18320–18326.
18. 18 Faul, C., Amaral, A.P., Oskouei, B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 121 (2011), 4393–4408.
19. 19 Grabner, A., Amaral, A.P., Schramm, K., et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22 (2015), 1020–1032.
20. 20 Kimmel, P.L., Phillips, T.M., Simmens, S.J., et al. Immunologic function and survival in hemodialysis patients. Kidney Int 54 (1998), 236–244.
21. 21 Stenvinkel, P., Inflammation in end-stage renal disease—a fire that burns within. Contrib Nephrol 149 (2005), 185–199.
22. 22 Barreto, D.V., Barreto, F.C., Liabeuf, S., et al., for the EUTox Work Group. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77 (2010), 550–556.
23. 23 Pereira, B.J., Shapiro, L., King, A.J., et al. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45 (1994), 890–896.
24. 24 Ridker, P.M., Cannon, C.P., Morrow, D., et al., for the PROVE IT-TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005), 20–28.
25. 25 Shlipak, M.G., Fried, L.F., Crump, C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003), 87–92.
26. 26 Munoz Mendoza, J., Isakova, T., Ricardo, A.C., et al., for the Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7 (2012), 1155–1162.
27. 27 David, V., Martin, A., Isakova, T., et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89 (2016), 135–146.
28. 28 Kan, M., Wu, X., Wang, F., McKeehan, W.L., Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 274 (1999), 15947–15952.
29. 29 Lin, B.C., Wang, M., Blackmore, C., Desnoyers, L.R., Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282 (2007), 27277–27284.
30. 30 Fon Tacer, K., Bookout, A.L., Ding, X., et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24 (2010), 2050–2064.
31. 31 Weinstein, M., Xu, X., Ohyama, K., Deng, C.X., FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125 (1998), 3615–3623.
32. 32 Partanen, J., Makela, T.P., Eerola, E., et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 10 (1991), 1347–1354.
33. 33 Yang, J., Rothermel, B., Vega, R.B., et al. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 87 (2000), E61–E68.
34. 34 Wilkins, B.J., Dai, Y.S., Bueno, O.F., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94 (2004), 110–118.
35. 35 Rao, A., Luo, C., Hogan, P.G., Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15 (1997), 707–747.
36. 36 Lu, Y.C., Yeh, W.C., Ohashi, P.S., LPS/TLR4 signal transduction pathway. Cytokine 42 (2008), 145–151.
37. 37 Kuro-o, M., Matsumura, Y., Aizawa, H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997), 45–51.
38. 38 Liu, F., Wu, S., Ren, H., Gu, J., Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat Cell Biol 13 (2011), 254–262.
39. 39 Eren, M., Boe, A.E., Murphy, S.B., et al. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A 111 (2014), 7090–7095.
40. 40 Hu, M.C., Shi, M., Cho, H.J., et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26 (2015), 1290–1302.
41. 41 Korish, A.A., Arafah, M.M., The potential anti-inflammatory effect of tetrahydrobiopterin administration in renal mass reduction-induced chronic renal failure in rats. Saudi Med J 28 (2007), 1803–1809.
42. 42 Di Marco, G.S., Reuter, S., Kentrup, D., et al. Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. Eur Heart J 32 (2011), 1935–1945.
43. 43 Nasrallah, M.M., El-Shehaby, A.R., Osman, N.A., et al. The association between fibroblast growth factor-23 and vascular calcification is mitigated by inflammation markers. Nephron Extra 3 (2013), 106–112.
44. 44 Manghat, P., Fraser, W.D., Wierzbicki, A.S., et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21 (2010), 1853–1861.
45. 45 Bacchetta, J., Dubourg, L., Harambat, J., et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 95 (2010), 1741–1748.
46. 46 Portale, A.A., Wolf, M., Juppner, H., et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 9 (2014), 344–353.
47. 47 Dai, B., David, V., Martin, A., et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One, 7, 2012, e44161.
48. 48 Masuda, Y., Ohta, H., Morita, Y., et al. Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol Pharm Bull 38 (2015), 687–693.
49. 49 Han, X., Li, L., Yang, J., et al. Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. FEBS Lett 590 (2016), 53–67.
50. 50 Yamauchi, M., Hirohashi, Y., Torigoe, T., et al. Wound healing delays in alpha-Klotho-deficient mice that have skin appearance similar to that in aged humans: study of delayed wound healing mechanism. Biochem Biophys Res Commun 473 (2016), 845–852.
51. 51 Holecki, M., Chudek, J., Owczarek, A., et al. Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly. Clin Endocrinol (Oxf) 82 (2015), 900–909.
52. 52 Hanks, L.J., Casazza, K., Judd, S.E., et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One, 10, 2015, e0122885.
53. 53 di Giuseppe, R., Kuhn, T., Hirche, F., et al. Potential predictors of plasma fibroblast growth factor 23 concentrations: cross-sectional analysis in the EPIC-Germany Study. PLoS One, 10, 2015, e0133580.
54. 54 Ito, N., Wijenayaka, A.R., Prideaux, M., et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol 399 (2015), 208–218.
55. 55 Pathak, J.L., Bakker, A.D., Luyten, F.P., et al. Systemic inflammation affects human osteocyte-specific protein and cytokine expression. Calcif Tissue Int 98 (2016), 596–608.
56. 56 Frey, N., Olson, E.N., Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003), 45–79.
57. 57 Kalkan, Y., Tomak, Y., Altuner, D., et al. Hepatic effects of ketamine administration for 2 weeks in rats. Hum Exp Toxicol 33 (2014), 32–40.
58. 58 Wang, S., Kang, X., Cao, S., et al. Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma. Dig Dis Sci 57 (2012), 3184–3188.
59. 59 Yu, C., Wang, F., Kan, M., et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275 (2000), 15482–15489.
60. 60 Yu, C., Wang, F., Jin, C., et al. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 280 (2005), 17707–17714.
61. 61 Huang, X., Yang, C., Luo, Y., et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56 (2007), 2501–2510.
62. 62 Owen, B.M., Mangelsdorf, D.J., Kliewer, S.A., Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab 26 (2015), 22–29.
63. 63 Yu, C., Wang, F., Jin, C., et al. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol 161 (2002), 2003–2010.
64. 64 Padrissa-Altes, S., Bachofner, M., Bogorad, R.L., et al. Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. Gut 64 (2015), 1444–1453.
65. 65 Ho, H.K., Pok, S., Streit, S., et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50 (2009), 118–127.
66. 66 Mellor, H.R., Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Liver Int 34 (2014), e1–e9.
67. 67 Weng, P.H., Hung, K.Y., Huang, H.L., et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 6 (2011), 1121–1128.
68. 68 Pepys, M.B., Hirschfield, G.M., 2003. C-reactive protein: a critical update. J Clin Invest 111 (2013), 1805–1812.
69. 69 Shimada, T., Kakitani, M., Yamazaki, Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004), 561–568.
70. 70 Shalhoub, V., Shatzen, E.M., Ward, S.C., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122 (2012), 2543–2553.
71. 71 Seitzer, N., Mayr, T., Streit, S., Ullrich, A., A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 70 (2010), 802–812.